financetom
Business
financetom
/
Business
/
Kazakhstan in talks with oil producers about output cuts, Ifx reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kazakhstan in talks with oil producers about output cuts, Ifx reports
Apr 10, 2025 4:20 AM

*

Kazakhstan says it exceeded OPEC+ output quota in March

*

Country pledges to fulfil its obligations in April

*

Kazakhstan says it didn't cut CPC oil exports in March

(Recasts, adds detail)

ALMATY, April 10 (Reuters) - Kazakhstan has been in

talks with oil producers about reducing output, which has been

above the country's OPEC+ quota, Interfax news agency reported

on Thursday citing the energy ministry.

Kazakhstan has been pumping oil above the limit agreed by

the Organization of the Petroleum Exporting Countries and its

allies led by Russia for months.

OPEC+ members have been pressing Kazakhstan to reduce output

to honour the agreed quotas.

Kazakhstan's energy ministry said on Thursday that the

country exceeded its OPEC+ quota in March but will fulfil its

commitments in April and partially compensate for earlier

overproduction, according to Interfax.

Numerous Western majors, such as Chevron ( CVX ), Shell

, ExxonMobil ( XOM ), TotalEnergies and Eni

, are active in Kazakhstan, a top 10 global oil

producer.

A production boost at the Chevron ( CVX )-led Tengiz oilfield,

Kazakhstan's largest, has been the main contributor to the

country's overall increase in oil output.

Interfax also cited the energy ministry as saying that

Kazakhstan did not cut oil exports via the Caspian Pipeline

Consortium (CPC) last month.

According to industry sources, expected Black Sea CPC Blend

oil exports for April were revised down. The pipeline's

infrastructure suffered from Ukrainian drone attacks in February

and March. Russia also restricted CPC's exporting capacity at

the Black Sea, which was partially restored earlier this week.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2025 - www.financetom.com All Rights Reserved